Identification
NameIxazomib
Accession NumberDB09570
TypeSmall Molecule
GroupsApproved
Description

Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration.

Structure
Thumb
SynonymsNot Available
External IDs MLN 2238 / MLN2238 / MLN9708
Product Ingredients
IngredientUNIICASInChI KeyDetails
ixazomib citrate46CWK97Z3K 1239908-20-3MBOMYENWWXQSNW-AWEZNQCLSA-NDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NinlaroCapsule2.3 mg/1OralMillennium Pharmaceuticals, Inc.2015-11-20Not applicableUs
NinlaroCapsule2.3 mgOralTakeda2016-09-21Not applicableCanada
NinlaroCapsule3 mg/1OralMillennium Pharmaceuticals, Inc.2015-11-20Not applicableUs
NinlaroCapsule3 mgOralTakeda2016-09-21Not applicableCanada
NinlaroCapsule4 mg/1OralMillennium Pharmaceuticals, Inc.2015-11-20Not applicableUs
NinlaroCapsule4 mgOralTakeda2016-09-21Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII71050168A2
CAS number1072833-77-2
WeightAverage: 361.03
Monoisotopic: 360.081492
Chemical FormulaC14H19BCl2N2O4
InChI KeyMXAYKZJJDUDWDS-LBPRGKRZSA-N
InChI
InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1
IUPAC Name
2-{[(2,5-dichlorophenyl)(hydroxy)methylidene]amino}-N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]ethanimidic acid
SMILES
[H][[email protected]@](CC(C)C)(N=C(O)CN=C(O)C1=C(Cl)C=CC(Cl)=C1)B(O)O
Pharmacology
Indication

Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Structured Indications
Pharmacodynamics

In vitro studies have shown ixazomib to induce apoptosis in multiple myeloma cells sensitive or resistant to other conventional therapies. In mouse xenograft models, ixazomib induced tumor growth inhibition.

Mechanism of action

Ixazomib is an N-capped dipeptidyl leucine boronic acid which reversibly inhibits the CT-L proteolytic (β5) site of the 20S proteasome. At higher concentrations, ixazomib also seems to inhibit the proteolytic β1 and β2 subunits and to induce accumulation of ubiquitinated proteins.

Related Articles
Absorption

After oral administration, the time to reach maximum concentration in plasma was 1 hour. The mean absolute oral bioavailability is 58%.

Volume of distribution

The steady-state volume of distribution is 543 L.

Protein binding

99%

Metabolism

Metabolism of ixazomib is expected to be by CYP and non-CYP pathways, with no predominant CYP isozyme contribution. At higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42%), 1A2 (26%), 2B6 (16%), 2C8 (6%), 2D6 (5%), 2C19 (5%) and 2C9 (<1%).

Route of elimination

62% in urine and 22% in feces.

Half life

Terminal half-life is 9.5 days.

ClearanceNot Available
Toxicity

Drug-induced liver injury, hepatocellular injury, hepatic steatosis, hepatitis cholestatic and hepatotoxicity have each been reported in <1% of patients. Ixazomib can cause fetal harm when administered to pregnant women, and therefore it should also be advised to women of reproductive age to avoid becoming pregnant on ixazomib.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Ixazomib.Approved, Investigational
AbirateroneThe serum concentration of Ixazomib can be increased when it is combined with Abiraterone.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ixazomib.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Ixazomib.Approved, Investigational
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Ixazomib.Approved, Illicit, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Ixazomib.Experimental
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Ixazomib.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Ixazomib.Approved
AmiodaroneThe metabolism of Ixazomib can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Ixazomib.Approved
AprepitantThe serum concentration of Ixazomib can be increased when it is combined with Aprepitant.Approved, Investigational
ArmodafinilThe metabolism of Ixazomib can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Ixazomib can be decreased when combined with Artemether.Approved
AtazanavirThe metabolism of Ixazomib can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Ixazomib can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Ixazomib.Approved
AzithromycinThe metabolism of Ixazomib can be decreased when combined with Azithromycin.Approved
BetaxololThe metabolism of Ixazomib can be decreased when combined with Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Ixazomib.Approved, Investigational
BexaroteneThe serum concentration of Ixazomib can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe serum concentration of Ixazomib can be decreased when it is combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Ixazomib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ixazomib can be decreased when it is combined with Bosentan.Approved, Investigational
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Ixazomib.Approved, Investigational
BupropionThe metabolism of Ixazomib can be decreased when combined with Bupropion.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ixazomib.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Ixazomib.Approved
CaffeineThe metabolism of Ixazomib can be decreased when combined with Caffeine.Approved
CapecitabineThe metabolism of Ixazomib can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe serum concentration of Ixazomib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CelecoxibThe metabolism of Ixazomib can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Ixazomib can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Ixazomib can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe metabolism of Ixazomib can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Ixazomib.Withdrawn
ChlorpromazineThe metabolism of Ixazomib can be decreased when combined with Chlorpromazine.Approved, Vet Approved
CholecalciferolThe metabolism of Ixazomib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Ixazomib can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Ixazomib can be decreased when combined with Cinacalcet.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Ixazomib.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Ixazomib can be decreased when combined with Citalopram.Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ixazomib.Approved
ClemastineThe metabolism of Ixazomib can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Ixazomib can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Ixazomib.Approved, Vet Approved
ClopidogrelThe metabolism of Ixazomib can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Ixazomib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Ixazomib can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Ixazomib can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Ixazomib can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Ixazomib can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Ixazomib.Approved
CrizotinibThe metabolism of Ixazomib can be decreased when combined with Crizotinib.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ixazomib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ixazomib.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Ixazomib.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Ixazomib can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Ixazomib can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Ixazomib can be decreased when it is combined with Dabrafenib.Approved
DarifenacinThe metabolism of Ixazomib can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Ixazomib can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ixazomib can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Ixazomib can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Ixazomib.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Ixazomib.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ixazomib.Approved
DexamethasoneThe serum concentration of Ixazomib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Ixazomib.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Ixazomib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ixazomib.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ixazomib.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Ixazomib.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Ixazomib.Approved
DiphenhydramineThe metabolism of Ixazomib can be decreased when combined with Diphenhydramine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ixazomib.Approved, Investigational
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Ixazomib.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Ixazomib.Approved
DoxorubicinThe metabolism of Ixazomib can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Ixazomib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Ixazomib can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Ixazomib can be decreased when combined with Duloxetine.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Ixazomib.Approved
EfavirenzThe serum concentration of Ixazomib can be decreased when it is combined with Efavirenz.Approved, Investigational
EliglustatThe metabolism of Ixazomib can be decreased when combined with Eliglustat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Ixazomib.Approved, Investigational
EnzalutamideThe serum concentration of Ixazomib can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ixazomib.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Ixazomib.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Ixazomib.Approved
ErythromycinThe metabolism of Ixazomib can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Ixazomib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Ixazomib.Investigational
EsomeprazoleThe metabolism of Ixazomib can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Ixazomib.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Ixazomib.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Ixazomib.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Ixazomib.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Ixazomib.Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Ixazomib.Approved
FelodipineThe metabolism of Ixazomib can be decreased when combined with Felodipine.Approved, Investigational
FloxuridineThe metabolism of Ixazomib can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Ixazomib can be decreased when combined with Fluconazole.Approved
FluorouracilThe metabolism of Ixazomib can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Ixazomib can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvastatinThe metabolism of Ixazomib can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Ixazomib can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ixazomib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ixazomib can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Ixazomib can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Ixazomib can be increased when it is combined with Fusidic Acid.Approved
GarlicThe serum concentration of Ixazomib can be decreased when it is combined with Garlic.Approved
GemfibrozilThe metabolism of Ixazomib can be decreased when combined with Gemfibrozil.Approved
HaloperidolThe metabolism of Ixazomib can be decreased when combined with Haloperidol.Approved
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Ixazomib.Withdrawn
IdelalisibThe serum concentration of Ixazomib can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Ixazomib can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Ixazomib.Approved
IndinavirThe metabolism of Ixazomib can be decreased when combined with Indinavir.Approved
IrbesartanThe metabolism of Ixazomib can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Ixazomib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Ixazomib can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Ixazomib can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Ixazomib can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ixazomib can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Ixazomib can be decreased when combined with Ketoconazole.Approved, Investigational
LapatinibThe metabolism of Ixazomib can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Ixazomib can be decreased when combined with Leflunomide.Approved, Investigational
LidocaineThe metabolism of Ixazomib can be decreased when combined with Lidocaine.Approved, Vet Approved
LopinavirThe metabolism of Ixazomib can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Ixazomib can be decreased when combined with Lorcaserin.Approved
LosartanThe metabolism of Ixazomib can be decreased when combined with Losartan.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Ixazomib.Approved, Investigational
LuliconazoleThe serum concentration of Ixazomib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Ixazomib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Ixazomib can be decreased when combined with Lumefantrine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Ixazomib.Approved
MethadoneThe metabolism of Ixazomib can be decreased when combined with Methadone.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Ixazomib.Experimental
MethotrimeprazineThe metabolism of Ixazomib can be decreased when combined with Methotrimeprazine.Approved
MetoprololThe metabolism of Ixazomib can be decreased when combined with Metoprolol.Approved, Investigational
MexiletineThe metabolism of Ixazomib can be decreased when combined with Mexiletine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ixazomib.Approved, Illicit
MifepristoneThe serum concentration of Ixazomib can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe metabolism of Ixazomib can be decreased when combined with Mirabegron.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Ixazomib.Approved
MitotaneThe serum concentration of Ixazomib can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Ixazomib can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Ixazomib can be decreased when it is combined with Modafinil.Approved, Investigational
NafcillinThe serum concentration of Ixazomib can be decreased when it is combined with Nafcillin.Approved
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Ixazomib.Approved, Withdrawn
NelfinavirThe metabolism of Ixazomib can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ixazomib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Ixazomib can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Ixazomib can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Ixazomib can be decreased when combined with Nilotinib.Approved, Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Ixazomib.Approved
OlaparibThe metabolism of Ixazomib can be decreased when combined with Olaparib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Ixazomib.Experimental
OmeprazoleThe metabolism of Ixazomib can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Ixazomib.Investigational
OsimertinibThe serum concentration of Ixazomib can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Ixazomib.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ixazomib.Approved, Vet Approved
PalbociclibThe serum concentration of Ixazomib can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Ixazomib can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Ixazomib can be decreased when combined with Pantoprazole.Approved
ParoxetineThe metabolism of Ixazomib can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Ixazomib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe serum concentration of Ixazomib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PethidineThe risk or severity of adverse effects can be increased when Ixazomib is combined with Pethidine.Approved
PhenobarbitalThe serum concentration of Ixazomib can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Ixazomib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Ixazomib.Approved
PioglitazoneThe metabolism of Ixazomib can be decreased when combined with Pioglitazone.Approved, Investigational
PosaconazoleThe metabolism of Ixazomib can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe serum concentration of Ixazomib can be decreased when it is combined with Primidone.Approved, Vet Approved
PromazineThe metabolism of Ixazomib can be decreased when combined with Promazine.Approved, Vet Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Ixazomib.Approved
PyrimethamineThe metabolism of Ixazomib can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Ixazomib can be increased when it is combined with Quazepam.Approved, Illicit
QuinidineThe metabolism of Ixazomib can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Ixazomib can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Ixazomib can be decreased when combined with Rabeprazole.Approved, Investigational
RanolazineThe metabolism of Ixazomib can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe serum concentration of Ixazomib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Ixazomib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Ixazomib can be decreased when it is combined with Rifapentine.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Ixazomib.Approved
RitonavirThe metabolism of Ixazomib can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Ixazomib can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Ixazomib can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Ixazomib can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ixazomib.Approved
SaquinavirThe metabolism of Ixazomib can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalThe metabolism of Ixazomib can be increased when combined with Secobarbital.Approved, Vet Approved
SertralineThe metabolism of Ixazomib can be decreased when combined with Sertraline.Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Ixazomib.Approved, Investigational
SiltuximabThe serum concentration of Ixazomib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Ixazomib.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ixazomib.Approved
SorafenibThe metabolism of Ixazomib can be decreased when combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Ixazomib can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StiripentolThe serum concentration of Ixazomib can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Ixazomib can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Ixazomib can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Ixazomib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Ixazomib.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Ixazomib.Approved, Investigational
TamoxifenThe metabolism of Ixazomib can be decreased when combined with Tamoxifen.Approved
TelaprevirThe metabolism of Ixazomib can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Ixazomib can be decreased when combined with Telithromycin.Approved
TemsirolimusThe risk or severity of adverse effects can be increased when Ixazomib is combined with Temsirolimus.Approved
Tenofovir disoproxilThe metabolism of Ixazomib can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe metabolism of Ixazomib can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Ixazomib can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Ixazomib can be decreased when combined with Theophylline.Approved
ThioridazineThe metabolism of Ixazomib can be decreased when combined with Thioridazine.Withdrawn
ThiotepaThe metabolism of Ixazomib can be decreased when combined with Thiotepa.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Ixazomib.Approved
TicagrelorThe metabolism of Ixazomib can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Ixazomib can be decreased when combined with Ticlopidine.Approved
TipranavirThe serum concentration of Ixazomib can be decreased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Ixazomib can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Ixazomib can be decreased when combined with Tolbutamide.Approved
TopiramateThe metabolism of Ixazomib can be decreased when combined with Topiramate.Approved
TranylcypromineThe metabolism of Ixazomib can be decreased when combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ixazomib.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Ixazomib.Approved
TrimethoprimThe metabolism of Ixazomib can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Ixazomib.Approved
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Ixazomib.Approved, Investigational
ValsartanThe metabolism of Ixazomib can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Ixazomib can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Ixazomib can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Ixazomib.Approved
VoriconazoleThe metabolism of Ixazomib can be decreased when combined with Voriconazole.Approved, Investigational
ZafirlukastThe metabolism of Ixazomib can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Ixazomib.Approved
ZiprasidoneThe metabolism of Ixazomib can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • A food effect study conducted in patients with a single 4 mg dose of ixazomib showed that a high-fat meal decreased ixazomib AUC by 28% and Cmax by 69%.
References
Synthesis ReferenceNot Available
General References
  1. Offidani M, Corvatta L, Caraffa P, Gentili S, Maracci L, Leoni P: An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. Onco Targets Ther. 2014 Sep 29;7:1793-800. doi: 10.2147/OTT.S49187. eCollection 2014. [PubMed:25302026 ]
  2. Gentile M, Offidani M, Vigna E, Corvatta L, Recchia AG, Morabito L, Morabito F, Gentili S: Ixazomib for the treatment of multiple myeloma. Expert Opin Investig Drugs. 2015;24(9):1287-98. doi: 10.1517/13543784.2015.1065250. Epub 2015 Jul 3. [PubMed:26138345 ]
External Links
ATC CodesL01XX50 — Ixazomib
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (463 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic ScienceGlioblastomas1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentAdvanced Solid Tumors / Malignant Lymphomas1
1Active Not RecruitingTreatmentLight-Chain Amyloidosis1
1Active Not RecruitingTreatmentRecurrent Adult Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia1
1CompletedTreatmentAdvanced Non-Hematologic Malignancies1
1CompletedTreatmentAdvanced Solid Tumors / Malignancies, Hematologic1
1CompletedTreatmentAdvanced Solid Tumors / Multiple Myeloma (MM)1
1CompletedTreatmentMalignant Lymphomas1
1CompletedTreatmentMultiple Myeloma (MM)2
1CompletedTreatmentRelapsed and Refractory Multiple Myeloma1
1Not Yet RecruitingTreatmentAcute Lymphoblastic Leukemia in Complete Remission / Lymphoblastic Lymphoma in Complete Remission / Mixed Phenotype Acute Leukemia in Complete Remission1
1RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B-cell Adult Acute Lymphoblastic Leukemia / Lymphoma, Lymphoblastic / T-cell Adult Acute Lymphoblastic Leukemia1
1RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
1RecruitingTreatmentCancer, Breast1
1RecruitingTreatmentCastration-Resistant Prostate Carcinoma / Leukemia, Plasma Cell / Prostate Carcinoma Metastatic in the Bone / Recurrent Plasma Cell Myeloma / Stage IV Prostate Cancer1
1RecruitingTreatmentHigh Risk Smoldering Multiple Myeloma / Multiple Myeloma (MM)1
1RecruitingTreatmentMultiple Myeloma (MM) / Relapsed and/or Refractory Multiple Myeloma1
1RecruitingTreatmentNephritis, Lupus1
1RecruitingTreatmentTumors, Solid1
1TerminatedTreatmentMixed Phenotype Acute Leukemia (MPAL) / Relapsed or Refractory Acute Lymphoblastic Leukemia / Relapsed or Refractory Lymphoblastic Lymphoma1
1, 2Active Not RecruitingTreatmentKahler Disease / Multiple Myeloma (MM) / Myeloma, Plasma-Cell / Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)3
1, 2Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2Not Yet RecruitingTreatmentAdult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma1
1, 2Not Yet RecruitingTreatmentLymphoma, B Cell / Malignant Lymphomas1
1, 2RecruitingTreatmentAmyloidosis / Plasma Cell Myeloma1
1, 2RecruitingTreatmentBladder Cancers1
1, 2RecruitingTreatmentHIV Disease1
1, 2RecruitingTreatmentHematopoietic Stem Cell Transplantation (HSCT) / Multiple Myeloma (MM)1
1, 2RecruitingTreatmentLoss of Chromosome 17p / Recurrent Plasma Cell Myeloma1
1, 2RecruitingTreatmentMantle Cell Lymphoma (MCL)1
1, 2RecruitingTreatmentMultiple Myeloma (MM)1
1, 2RecruitingTreatmentPatients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation1
1, 2RecruitingTreatmentPlasma Cell Myeloma1
1, 2RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
1, 2SuspendedTreatmentMultiple Myeloma in Relapse1
1, 2TerminatedTreatmentMetastatic Renal Cell Carcinoma / RCC1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)1
2Active Not RecruitingTreatmentNewly Diagnosed Multiple Myeloma1
2Active Not RecruitingTreatmentPlasma Cell Myeloma1
2Active Not RecruitingTreatmentT-Cell Lymphomas1
2Active Not RecruitingTreatmentWaldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentFollicular Lymphoma (FL)1
2Not Yet RecruitingTreatmentPlasma Cell Myeloma1
2Not Yet RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2RecruitingPreventionChronic Leukemias / Leukaemia, Acute / Malignant Lymphomas / Multiple Myeloma (MM) / Myelodysplastic Syndrome1
2RecruitingTreatmentAmyloidosis / Malignant Lymphomas / Multiple Myeloma (MM)1
2RecruitingTreatmentB-cell Non-Hodgkin's Lymphomas / Chronic Lymphocytic Leukaemia (CLL) / Follicular Lymphoma (FL) / Lymphoplasmacytic Lymphoma / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Small Lymphocytic Lymphoma (SLL) / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentChronic Graft Versus Host Disease1
2RecruitingTreatmentLeukemia, Plasma Cell / Plasma Cell Myeloma / Plasmacytoma1
2RecruitingTreatmentLymphoid Hematologic Malignancy / Myeloid Hematologic Malignancy1
2RecruitingTreatmentMultiple Myeloma (MM)9
2RecruitingTreatmentPlasmacytoma / POEMS Syndrome1
2RecruitingTreatmentPlasma Cell Myeloma / Residual Disease1
2RecruitingTreatmentPlasma Cell Myeloma / Transplant-Related Carcinoma1
2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma2
2RecruitingTreatmentSmoldering Multiple Myeloma (SMM)1
2TerminatedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
2WithdrawnTreatmentMultiple Myeloma (MM)2
2, 3RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
3Active Not RecruitingTreatmentAutologous Stem Cell Transplant / Multiple Myeloma (MM)1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
3Active Not RecruitingTreatmentRefractory Multiple Myeloma / Relapsed Multiple Myeloma1
3RecruitingTreatmentMultiple Myeloma (MM)2
3RecruitingTreatmentRelapsed or Refractory Systemic Light Chain Amyloidosis1
3RecruitingTreatmentSolitary Osseous Plasmacytoma1
4Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
CapsuleOral2.3 mg/1
CapsuleOral2.3 mg
CapsuleOral3 mg/1
CapsuleOral3 mg
CapsuleOral4 mg
CapsuleOral4 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8871745 No2007-08-062027-08-06Us
US8530694 No2007-08-062027-08-06Us
US7442830 No2007-08-062027-08-06Us
US9175017 No2009-06-162029-06-16Us
US8003819 No2007-08-062027-08-06Us
US9233115 No2004-08-122024-08-12Us
US8546608 No2004-08-122024-08-12Us
US7687662 No2007-08-062027-08-06Us
US8859504 No2009-06-162029-06-16Us
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0179 mg/mLALOGPS
logP2.82ALOGPS
logP4.27ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)3.47ChemAxon
pKa (Strongest Basic)1.63ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area105.64 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity85.6 m3·mol-1ChemAxon
Polarizability36.45 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as hippuric acids and derivatives. These are compounds containing a hippuric acid or a derivative, with a structure characterized the presence of a benzoyl group linked to the N-terminal of a glycine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentHippuric acids and derivatives
Alternative ParentsN-acyl-alpha amino acids and derivatives / Alpha amino acid amides / 2-halobenzoic acids and derivatives / 3-halobenzoic acids and derivatives / Benzoyl derivatives / Dichlorobenzenes / Aryl chlorides / Vinylogous halides / Secondary carboxylic acid amides / Boronic acids
SubstituentsHippuric acid or derivatives / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / N-substituted-alpha-amino acid / Alpha-amino acid or derivatives / Halobenzoic acid or derivatives / 3-halobenzoic acid or derivatives / 2-halobenzoic acid or derivatives / Benzoyl / 1,4-dichlorobenzene
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Uniprot Name:
Cytochrome P450 1A2
Molecular Weight:
58293.76 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Uniprot Name:
Cytochrome P450 2B6
Molecular Weight:
56277.81 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Uniprot Name:
Cytochrome P450 2C8
Molecular Weight:
55824.275 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Uniprot Name:
Cytochrome P450 2D6
Molecular Weight:
55768.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Uniprot Name:
Cytochrome P450 2C19
Molecular Weight:
55930.545 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Uniprot Name:
Cytochrome P450 2C9
Molecular Weight:
55627.365 Da
Drug created on November 30, 2015 12:10 / Updated on September 01, 2017 12:06